Xiufen Zheng

Dr. Xiufen Zheng

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MAM‐Ashraf Altesha
M‐Ashraf Altesha
TNTiffany Ni
Tiffany Ni
AKAfaan Khan
Afaan Khan
KLKexiang Liu
Kexiang Liu
XZXiufen Zheng
Xiufen Zheng

13 October 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
KLKe Xin Lin
Ke Xin Lin
AIAlexandra C. Istl
Alexandra C. Istl
DQDouglas Quan
Douglas Quan
ASAnton Skaro
Anton Skaro
ETEphraim Tang
Ephraim Tang
XZXiufen Zheng
Xiufen Zheng
Colorectal cancer (CRC) is the second most common cause of cancer mortality, with mismatch repair proficient (pMMR) and/or microsatellite stable (MSS) CRC making up more than 80% of metastatic CRC. Programmed death-ligand 1 (PD-L1) and programmed death 1 (PD-1) immune checkpoint inhibitors (ICIs) are approved as monotherapy in many cancers including a subset of advanced or metastatic colorectal cancer (CRC) with deficiency in mismatch repair (dMMR) and/or high microsatellite instability (MSI-H). However, proficient mismatch repair and microsatellite stable (pMMR/MSS) cold CRCs have not shown clinical response to ICIs alone. To potentiate the anti-tumor response of PD-L1/PD-1 inhibitors in patients with MSS cold cancer, combination strategies currently being investigated include dual ICI, and PD-L1/PD-1 inhibitors in combination with chemotherapy, radiotherapy, vascular endothelial growth factor (VEGF) /VEGF receptor (VEGFR) inhibitors, mitogen-activated protein kinase (MEK) inhibitors, and signal transducer and activation of transcription 3 (STAT3) inhibitors. This paper will review the mechanisms of PD-1/PD-L1 ICI resistance in pMMR/MSS CRC and potential combination strategies to overcome this resistance, summarize the published clinical experience with different combination therapies, and make recommendations for future avenues of research.

20 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
QLQing Li
Qing Li
NJNathan Johnston
Nathan Johnston
XZXiufen Zheng
Xiufen Zheng
HWHongmei Wang
Hongmei Wang
XZXusheng Zhang
Xusheng Zhang
WMWei-Ping Min
Wei-Ping Min
MiR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion

21 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PAPalida Abulizi
Palida Abulizi
NLNeruja Loganathan
Neruja Loganathan
DZDuo Zhao
Duo Zhao
TMTina Mele
Tina Mele
YZYixin Zhang
Yixin Zhang
XZXiufen Zheng
Xiufen Zheng
Septic acute kidney injury (AKI) and myocardial dysfunction are leading causes of mortality with no accepted method of therapy. In this study we demonstrate the role of growth differentiating factor 15 (GDF15) in septic AKI and myocardial dysfunction using a murine lipopolysaccharide (LPS)-induced sepsis model and anin vitrocell culture system. Data show that GDF15 deficiency augments inflammatory response and exacerbates renal and cardiac injury induced by LPS, while over-expression of GDF15 protects the kidney and heart from LPS-induced organ dysfunction. Therefore, this study highlights the therapeutic potential of GDF15 in the treatment of endotoxin-induced sepsis.

22 July 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
TIThomas Ichim
Thomas Ichim
ZZZhaohui Zhong
Zhaohui Zhong
SKShalesh Kaushal
Shalesh Kaushal
XZXiufen Zheng
Xiufen Zheng
XRXiubao Ren
Xiubao Ren
RTRichard H Tullis
Richard H Tullis
Advances in cancer therapy have been substantial in terms of molecular understanding of disease mechanisms, however these advances have not translated into increased survival in the majority of cancer types. One unsolved problem in current cancer therapeutics is the substantial immune suppression seen in patients. Conventionally, investigations in this area have focused on antigen-nonspecific immune suppressive molecules such as cytokines and T cell apoptosis inducing molecules such as Fas ligand. More recently, studies have demonstrated nanovesicle particles termed exosomes are involved not only in stimulation but also inhibition of immunity in physiological conditions. Interestingly, exosomes secreted by cancer cells have been demonstrated to express tumor antigens, as well as immune suppressive molecules such as PD-1L and FasL. Concentrations of exosomes from plasma of cancer patients have been associated with spontaneous T cell apoptosis, which is associated in some situations with shortened survival. In this paper we place the "exosome-immune suppression" concept in perspective of other tumor immune evasion mechanisms. We conclude by discussing a novel therapeutic approach to cancer immune suppression by extracorporeal removal of exosomes using hollow fiber filtration technology

2 July 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
XZXiufen Zheng
Xiufen Zheng
JKJames Koropatnick
James Koropatnick
DCDi Chen
Di Chen
TVThomas Velenosi
Thomas Velenosi
HLHong Ling
Hong Ling
WMWei-Ping Min
Wei-Ping Min
Cancer immunotherapeutic agents (vaccines) in the form of antigen‐loaded dendritic cells (DCs) reached an important milestone with the recent approval of Provenge, the first DC vaccine for treatment of prostate cancer. Although this heralds a new era of tumor immunotherapy, it also highlights the compelling need to optimize such DC‐based therapies as they are increasingly tested and used to treat human patients. In this study we sought to augment and enhance the antitumor activity of a DC‐based vaccine using siRNA to silence expression of immunosuppressive enzyme indoleamine 2,3‐dioxygenase (IDO) in DCs. We report here that DCs loaded with tumor antigens, but with siRNA‐silenced IDO expression, were introduced into 4T1 breast tumor‐bearing mice, the treatment: (i) lengthened the time required for tumor onset, (ii) decreased tumor size compared to tumors grown for equal lengths of time in mice treated with antigen‐loaded DCs without IDO silencing and (iii) reduced CD4+ and CD8+ T cell apoptosis. Furthermore, immunization with IDO‐silenced DCs enhanced tumor antigen‐specific T cell proliferation and CTL activity, and decreased numbers of CD4+CD25+Foxp3+ Treg. This study provides evidence to support silencing of immunosuppressive genes (IDO) as an effective strategy to enhance the efficacy of DC‐based cancer immunotherapeutic.